Previous 10 | Next 10 |
Nutriband (NASDAQ:NTRB) announced a share repurchase program to buy back up to $1M of its stock. As of Dec.29, the company had 7.8M shares outstanding. YTD, the stock has lost 78.3%. Shares trading 20.1% higher premarket. For further details see: Nutriband rallies on launching...
ORLANDO, FL / ACCESSWIRE / December 29, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the Company had 7,773,962 shares of common stock outstanding. About Nutriband Inc. ...
Nutriband (NASDAQ:NTRB) has plans to start offering contract manufacturing services for liquid based topical, transdermal and cosmetic product's. "Our goal is to continue to expand our contract manufacturing capabilities to enhance the Company's revenue opportunities. Adding liquid based...
ORLANDO, FL / ACCESSWIRE / December 21, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced plans to start offering contrac...
ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its manufacturing subsidia...
ORLANDO, FL / ACCESSWIRE / December 3, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, today announced that its Chief Executive Officer...
ORLANDO, FL / ACCESSWIRE / November 16, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services, and the manufacture of transdermal products, has commenced the development of its lead produ...
ORLANDO, FL / ACCESSWIRE / November 10, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical products, contract research and development services and the manufacture of transdermal, topical and coated products, today announced that an inte...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...
Nutriband is advancing the development of transdermal products for currently injected compounds. The Company’s lead product candidate is an abuse deterrent fentanyl patch incorporating its AVERSA technology. The Company uplisted to Nasdaq effective 10/1/2021. For furt...
News, Short Squeeze, Breakout and More Instantly...
Nutriband (NASDAQ: NTRB) , a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and Preside...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Cha...
Nutriband (NASDAQ: NTRB) , a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registrat...